MedTrace Logo

Hemostatic Complications in Hematopoietic Stem Cell Transplantation

NCT02281240 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2015-10-08

No results posted yet for this study

Summary

Hemostatic disorders are common and potentially fatal complications in patients undergoing hematopoietic stem-cell transplantation (HSCT). Limited data exist on early diagnosis and prevention of these complications. The investigators undertook this prospective study to determine the incidence, predictor factors, specific pathogenesis, management and survival specially for patients with thrombotic and bleeding complication to better improve outcomes.

Conditions

  • Hemostatic Disorders

Interventions

DRUG

thrombopoietin, interleukin-11, heparin,

The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Jia Chen, Doctor · The First Affiliated Hospital of Soochow University

Eligibility

Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02281240 on ClinicalTrials.gov